Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Boothe talks with “The Pink Sheet” DAILY about Actavis’ global and U.S. strategies as the top five generics company looks to keep growing.
You may also be interested in...
Actavis Gets New CEO As Growth Strategy Shifts To Targeted Buys
As Actavis revamps its manufacturing strategy in New Jersey, the firm will have new leadership at its headquarters in Hafnarfjordur, Iceland. Robert Wessman stepped down as CEO of Actavis Group Aug. 5, after serving in the position with Actavis Group for nearly 10 years. Wessman, who will remain on the Board of Directors, wants to focus on his company, Salt Investments.
Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Boothe talks with “The Pink Sheet” DAILY about follow-on biologics and other issues facing the generics industry, as well as how the top-five generics company is positioning itself to thrive in an evolving global environment.
Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Boothe talks with “The Pink Sheet” DAILY about follow-on biologics and other issues facing the generics industry, as well as how the top-five generics company is positioning itself to thrive in an evolving global environment.